Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Home Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting
Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)
Mohammad Hirmand, MD

Comments

Comments are closed.